AU2012274639B2 - Novel compound with amyloid affinity - Google Patents

Novel compound with amyloid affinity Download PDF

Info

Publication number
AU2012274639B2
AU2012274639B2 AU2012274639A AU2012274639A AU2012274639B2 AU 2012274639 B2 AU2012274639 B2 AU 2012274639B2 AU 2012274639 A AU2012274639 A AU 2012274639A AU 2012274639 A AU2012274639 A AU 2012274639A AU 2012274639 B2 AU2012274639 B2 AU 2012274639B2
Authority
AU
Australia
Prior art keywords
pyridine
compound
triazole
imidazo
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012274639A
Other languages
English (en)
Other versions
AU2012274639A1 (en
Inventor
Yoshifumi Maya
Yuki Okumura
Takako Onishi
Yoshinari Shoyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Original Assignee
Nihon Medi Physics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Medi Physics Co Ltd filed Critical Nihon Medi Physics Co Ltd
Publication of AU2012274639A1 publication Critical patent/AU2012274639A1/en
Application granted granted Critical
Publication of AU2012274639B2 publication Critical patent/AU2012274639B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2012274639A 2011-06-24 2012-05-29 Novel compound with amyloid affinity Ceased AU2012274639B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-140069 2011-06-24
JP2011140069 2011-06-24
PCT/JP2012/063726 WO2012176587A1 (ja) 2011-06-24 2012-05-29 新規アミロイド親和性化合物

Publications (2)

Publication Number Publication Date
AU2012274639A1 AU2012274639A1 (en) 2014-02-06
AU2012274639B2 true AU2012274639B2 (en) 2016-08-11

Family

ID=47422429

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012274639A Ceased AU2012274639B2 (en) 2011-06-24 2012-05-29 Novel compound with amyloid affinity

Country Status (11)

Country Link
US (1) US9211350B2 (OSRAM)
EP (1) EP2725027B1 (OSRAM)
JP (1) JP5167436B2 (OSRAM)
KR (1) KR101854228B1 (OSRAM)
CN (1) CN103596950B (OSRAM)
AU (1) AU2012274639B2 (OSRAM)
CA (1) CA2839199C (OSRAM)
ES (1) ES2619830T3 (OSRAM)
IN (1) IN2014DN00185A (OSRAM)
TW (1) TWI554511B (OSRAM)
WO (1) WO2012176587A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3197277T3 (da) * 2014-08-29 2022-01-31 Chdi Foundation Inc Prober til billeddannelse af huntingtin-protein
US20200276338A1 (en) * 2017-09-19 2020-09-03 The Governors Of The University Of Alberta Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer
JP6831802B2 (ja) * 2018-01-12 2021-02-17 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． 放射性核種標識化合物及びこれを含有するイメージング剤
JPWO2022244680A1 (OSRAM) * 2021-05-18 2022-11-24

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033080A2 (en) * 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
WO2009155024A1 (en) * 2008-05-30 2009-12-23 Merck & Co., Inc. Novel substituted indoles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340394A1 (en) 1998-08-20 2000-03-02 Jorge R. Barrio Methods for labeling .beta.-amyloid plaques and neurofibrillary tangles
HU230581B1 (hu) 2000-08-24 2017-01-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
DE60217090T2 (de) 2001-04-23 2007-07-12 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
KR100947913B1 (ko) 2001-08-27 2010-03-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 스틸벤 유도체 및 이것을 아밀로이드 플라크의 결합 및영상화에 사용하는 용도
US8022075B2 (en) * 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
ES2376491T3 (es) 2006-05-19 2012-03-14 Nihon Medi-Physics Co., Ltd. Compuesto que tiene afinidad por amiloide.
KR20090025282A (ko) 2006-06-21 2009-03-10 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
CA2670436A1 (en) 2006-11-30 2008-06-05 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
EP2125800A1 (en) 2007-01-22 2009-12-02 AstraZeneca AB Novel heteroaryl substituted imidazo ý1,2 -a¨pyridine derivatives
EP2213672A4 (en) 2007-10-24 2012-05-02 Nihon Mediphysics Co Ltd NEW CONNECTION WITH AFFINITY TO AMYLOID
JP5313158B2 (ja) 2007-10-26 2013-10-09 日本メジフィジックス株式会社 新規アミロイド親和性化合物
TW200918103A (en) 2007-10-30 2009-05-01 Nihon Mediphysics Co Ltd Use of novel compound having affinity for amyloid, and process for production of the same
CA2704172A1 (en) 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
TW200922629A (en) * 2007-10-30 2009-06-01 Nihon Mediphysics Co Ltd Utilization of novel compounds with amyloid affinity and method of producing the same
EP2218464A1 (en) 2009-02-11 2010-08-18 Technische Universität München Compounds for non-invasive measurement of aggregates of amyloid peptides
WO2010128595A1 (ja) 2009-05-07 2010-11-11 富士フイルムＲｉファーマ株式会社 放射性ヨウ素標識イミダゾピリジン誘導体の製造法
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
CN103534253B (zh) * 2011-05-20 2016-02-24 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033080A2 (en) * 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
WO2009155024A1 (en) * 2008-05-30 2009-12-23 Merck & Co., Inc. Novel substituted indoles

Also Published As

Publication number Publication date
KR20140040735A (ko) 2014-04-03
CN103596950A (zh) 2014-02-19
CA2839199A1 (en) 2012-12-27
AU2012274639A1 (en) 2014-02-06
EP2725027A4 (en) 2015-02-25
US9211350B2 (en) 2015-12-15
EP2725027A1 (en) 2014-04-30
JP5167436B2 (ja) 2013-03-21
US20140121377A1 (en) 2014-05-01
CA2839199C (en) 2018-11-06
KR101854228B1 (ko) 2018-05-03
IN2014DN00185A (OSRAM) 2015-07-10
JPWO2012176587A1 (ja) 2015-02-23
TWI554511B (zh) 2016-10-21
EP2725027B1 (en) 2017-03-01
WO2012176587A1 (ja) 2012-12-27
TW201300388A (zh) 2013-01-01
CN103596950B (zh) 2017-12-19
ES2619830T3 (es) 2017-06-27

Similar Documents

Publication Publication Date Title
AU2012259929B2 (en) Novel compound having affinity for amyloid
US20100249418A1 (en) Novel compound having affinity for amyloid
CN101903383A (zh) 对淀粉样蛋白具有亲和性的新化合物
JP5180838B2 (ja) 新規アミロイド親和性化合物
AU2012274639B2 (en) Novel compound with amyloid affinity
US20100267952A1 (en) Use of novel compound having affinity for amyloid, and process for production of the same
US20100216994A1 (en) Use of novel compound having affinity for amyloid, and process for production of the same
US20100249408A1 (en) Use of novel compound having affinity for amyloid, and process for production of the same
HK1193605A (en) Novel compound with amyloid affinity
HK1193605B (en) Novel compound with amyloid affinity
HK1193815B (en) Compound having affinity for amyloid
JP2009120591A (ja) 新規アミロイド親和性化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired